Ottawa, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The global optic nerve atrophy treatment market size is calculated at USD 2.75 billion in 2025 and is expected to reach around USD 5.87 billion by 2034, ...

Please provide your email address to receive an email when new articles are posted on . Band optic atrophy is described as a horizontal band of optic disc pallor, often associated with a contralateral ...

Optic atrophy is a degenerative disease of the optic nerve that leads to gradual damage to the retinal ganglion cells —the nerve cells that transmit visual signals from the retina to the brain. The ...

Optic atrophy is a degenerative disease of the optic nerve that leads to gradual damage to the retinal ganglion cells - the nerve cells that transmit visual signals from the retina to the brain. The ...

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthal ...

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 20 ...

– Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression and clinical assessments – – ADOA is a ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...